NAFLD is considered by many as the hepatic manifestation of the metabolic syndrome, currently conceptualized as a state of chronic low-grade inflammation. NASH is the progressive form of NAFLD and ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic steatohepatitis (NASH)—occurs when fat buildup in the liver causes liver ...

In the early stages, fatty liver may be asymptomatic, with most people unaware they have it. However, continued fat buildup ...

MASH is the updated term for a type of liver disease once known as nonalcoholic steatohepatitis (NASH ... reduce fat and inflammation in MASH and may reverse the early stages of liver scarring.

Gilead's top late-stage drug selonsertib ... be announced later this year. NASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver, which ...

The therapy inhibits the inflammation that turns an ... mortality rate in these patients is high. NASH is less deadly, particularly in its early stages, but affects a large and growing number ...

Novartis has added another non-alcoholic steatohepatitis (NASH) drug candidate to its pipeline ... The agreement focuses on PLN-1474, a preclinical-stage drug that works as a small-molecule ...

NASH is a complex liver disease marked by too much fat buildup in liver cells and inflammation. To create precise treatments, it is crucial to fully grasp how NASH-related biomarkers work in both ...

Axcella (Nasdaq: AXLA) is a clinical-stage biotechnology ... nonalcoholic steatohepatitis (NASH), is characterized by dysregulated metabolism, inflammation and fibrosis. According to Axcella ...

The presence of inflammation on liver biopsy is associated with the development of advanced fibrosis in NASH. The presence of acinar inflammation is essential for the histological diagnosis of ...